Gritstone bio, Inc.

NASDAQ:GRTS

0.55 (USD) • At close September 13, 2024
Bedrijfsnaam Gritstone bio, Inc.
Symbool GRTS
Munteenheid USD
Prijs 0.551
Beurswaarde 65,030,815
Dividendpercentage 0%
52-weken bereik 0.42 - 3.33
Industrie Biotechnology
Sector Healthcare
CEO Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Website https://gritstonebio.com

An error occurred while fetching data.

Over Gritstone bio, Inc.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.

Vergelijkbare Aandelen

CorMedix Inc. logo

CorMedix Inc.

CRMD

6.95 USD

Gamida Cell Ltd. logo

Gamida Cell Ltd.

GMDA

0.033 USD

ORIC Pharmaceuticals, Inc. logo

ORIC Pharmaceuticals, Inc.

ORIC

9.89 USD

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.16 USD

Graphite Bio, Inc. logo

Graphite Bio, Inc.

GRPH

3.18 USD

Pieris Pharmaceuticals, Inc. logo

Pieris Pharmaceuticals, Inc.

PIRS

16.67 USD

Genenta Science S.p.A. logo

Genenta Science S.p.A.

GNTA

3.95 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)